Neurocrine Biosciences, Inc. is a pharmaceutical company in the United States specializing in products related to the central nervous system and endocrine system. With a medium risk ESG score of 22.0, the company is known for its late-stage clinical programs including elagolix for women's health, opicapone for Parkinson's patients, and ingrezza for Tourette syndrome.